124 related articles for article (PubMed ID: 15262294)
1. Management of metabolic syndrome: statins.
Xydakis AM; Ballantyne CM
Endocrinol Metab Clin North Am; 2004 Sep; 33(3):509-23, vi. PubMed ID: 15262294
[TBL] [Abstract][Full Text] [Related]
2. Summary of the role of statins in the treatment of dyslipidemia.
Carr LL
J Am Osteopath Assoc; 2003 Jul; 103(7 Suppl 3):S1-3. PubMed ID: 12884937
[No Abstract] [Full Text] [Related]
3. The metabolic syndrome: prevalence, CHD risk, and treatment.
Sarti C; Gallagher J
J Diabetes Complications; 2006; 20(2):121-32. PubMed ID: 16504841
[TBL] [Abstract][Full Text] [Related]
4. Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy.
Vega GL
Endocrinol Metab Clin North Am; 2004 Sep; 33(3):525-44, vi. PubMed ID: 15262295
[TBL] [Abstract][Full Text] [Related]
5. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
Turhan H; Yetkin E
Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
[TBL] [Abstract][Full Text] [Related]
6. Management of dyslipidemia in patients with complicated metabolic syndrome.
Davidson MH
Am J Cardiol; 2005 Aug; 96(4A):22E-25E. PubMed ID: 16098839
[TBL] [Abstract][Full Text] [Related]
7. [Statins].
Kobayashi J
Nihon Rinsho; 2006 Dec; 64 Suppl 9():618-21. PubMed ID: 17458292
[No Abstract] [Full Text] [Related]
8. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
9. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
Rosenson RS
Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
[TBL] [Abstract][Full Text] [Related]
10. [Effect of statin treatment on metabolic syndrome].
Kobayashi J
Nihon Rinsho; 2011 Jan; 69 Suppl 1():609-13. PubMed ID: 21766669
[No Abstract] [Full Text] [Related]
11. Effect of 80 mg/day simvastatin therapy on cardiovascular outcomes in adults with versus without metabolic syndrome.
Kamalesh M; Rao R; Sawada S; Friend A; Schellhase E; Evans T
Am J Cardiol; 2006 May; 97(10):1487-9. PubMed ID: 16679089
[TBL] [Abstract][Full Text] [Related]
12. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evidence of statins and fibrates in the management of dyslipidemia in Japan].
Hara M; Kinoshita M
Nihon Rinsho; 2011 Jan; 69 Suppl 1():621-5. PubMed ID: 21766671
[No Abstract] [Full Text] [Related]
14. Treating dyslipidemia in high-risk patients: case reviews and discussion.
Deedwania PC; Davidson MH; Ballantyne CM
Postgrad Med; 2004 Sep; 116(3 Suppl):21-8. PubMed ID: 19667672
[TBL] [Abstract][Full Text] [Related]
15. Therapy and clinical trials: metabolic syndrome and cardiovascular risk management.
Edavalath M; Rees A
Curr Opin Lipidol; 2008 Aug; 19(4):438-9. PubMed ID: 18607195
[No Abstract] [Full Text] [Related]
16. Diabetes and metabolic syndrome (MS).
Bellomo A; Mancinella M; Troisi G; Ettorre E; Marigliano V
Arch Gerontol Geriatr; 2007; 44 Suppl 1():61-7. PubMed ID: 17317435
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
[TBL] [Abstract][Full Text] [Related]
18. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
19. Hyperlipidaemia and cardiovascular disease: nonlipid-lowering effects of omega-3 fatty acids, statins and fibrates.
Dominiczak M
Curr Opin Lipidol; 2009 Feb; 20(1):79-81. PubMed ID: 19106712
[No Abstract] [Full Text] [Related]
20. Long-term risk reduction: who needs treatment?
Betteridge DJ
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl 2():S15-22. PubMed ID: 15885846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
